Compare Danaher Corporation (DHR) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs UiPath Inc — how do they compare? Danaher Corporation trades at $208.18 (market cap $147.18B), while UiPath Inc trades at $15.64 (market cap $8.08B). The key difference: Danaher Corporation is far larger — about 18.2× UiPath Inc's market cap, and Danaher Corporation pays a 0.76% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| DHR | PATH | |
|---|---|---|
Market Cap | $147.18B | $8.08B |
Sector | Health | Technology |
52-Week High | $242.05 | $19.29 |
52-Week Low | $161.91 | $9.38 |
Enterprise Value | $169.39B | $6.85B |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $204.76, up 2.37% today, near its pivot point of $203 with bullish technical signals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.92 EPS. Revenue for 2025 was $24.57B with a net income margin of 15.95%, though margins have trended down from 22.9% in 2022. Recent news includes the Masimo acquisition approval and a $172.5 million settlement over pandemic-era disclosures (Reuters, 2026-04-23).
Outlook is positive with strong analyst support (69% buy ratings) and a consensus price target of $202.33, slightly below current price. Risks include margin compression, high valuation (P/E 36.5), and integration challenges from acquisitions. Cash flow improved to $2.54B net in 2025 after a dip in 2023-2024, supporting dividend payments and growth initiatives.
UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.
PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
